n/a
Abstract Title:

Guillain-Barré Syndrome Variant Occurring after SARS-CoV-2 Vaccination.

Abstract Source:

Ann Neurol. 2021 08 ;90(2):315-318. Epub 2021 Jul 2. PMID: 34114269

Abstract Author(s):

Christopher Martin Allen, Shelby Ramsamy, Alexander William Tarr, Patrick Jason Tighe, William Lucien Irving, Radu Tanasescu, Jonathan Rhys Evans

Article Affiliation:

Christopher Martin Allen

Abstract:

Although SARS-CoV-2 vaccines are very safe, we report 4 cases of the bifacial weakness with paresthesias variant of Guillain-Barré syndrome (GBS) occurring within 3 weeks of vaccination with the Oxford-AstraZeneca SARS-CoV-2 vaccine. This rare neurological syndrome has previously been reported in association with SARS-CoV-2 infection itself. Our cases were given either intravenous immunoglobulin, oral steroids, or no treatment. We suggest vigilance for cases of bifacial weakness with paresthesias variant GBS following vaccination for SARS-CoV-2 and that postvaccination surveillance programs ensure robust data capture of this outcome, to assess for causality. ANN NEUROL 2021;90:315-318.

Study Type : Human: Case Report

Print Options


Key Research Topics

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2024 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.